Cartesian Therapeutics (RNAC) Return on Sales (2016 - 2026)
Cartesian Therapeutics (RNAC) has disclosed Return on Sales for 12 consecutive years, with 326.58% as the latest value for Q1 2026.
- For Q1 2026, Return on Sales fell 30851.0% year-over-year to 326.58%; the TTM value through Mar 2026 reached 154.81%, up 15613.0%, while the annual FY2025 figure was 325.76%, 32373.0% down from the prior year.
- Return on Sales hit 326.58% in Q1 2026 for Cartesian Therapeutics, down from 53.36% in the prior quarter.
- Across five years, Return on Sales topped out at 53.36% in Q4 2025 and bottomed at 880.18% in Q2 2025.
- Average Return on Sales over 5 years is 74.63%, with a median of 2.09% recorded in 2024.
- Year-over-year, Return on Sales surged 4117bps in 2024 and then crashed -88063bps in 2025.
- Cartesian Therapeutics' Return on Sales stood at 0.35% in 2022, then tumbled by -6880bps to 23.79% in 2023, then skyrocketed by 173bps to 17.38% in 2024, then skyrocketed by 207bps to 53.36% in 2025, then plummeted by -712bps to 326.58% in 2026.
- According to Business Quant data, Return on Sales over the past three periods came in at 326.58%, 53.36%, and 43.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.